Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3 results

Results by year

Filters applied: . Clear all
Page 1
Clinical predictors of 3-month isoniazid rifapentine (3HP)-related adverse drug reactions (ADR) during tuberculosis preventive therapy (PAnDoRA-3HP study): an observational study protocol.
Sekaggya-Wiltshire C, Mbabazi I, Nabisere RM, Alinaitwe L, Otaalo B, Aber F, Nampala J, Owori R, Bayigga J, Mayito J, Banturaki G, Laker EAO, Castelnuovo B, Sekadde MP, Pasipanodya J, Dooley KE, Stavia T, Zawedde-Muyanja S. Sekaggya-Wiltshire C, et al. Among authors: laker eao. BMJ Open. 2024 Dec 31;14(12):e088389. doi: 10.1136/bmjopen-2024-088389. BMJ Open. 2024. PMID: 39740953 Free PMC article.
The Potential Teratogenicity Alert for Women Conceiving on Dolutegravir-Based Regimens: An Assessment of Risk Communication by an Urban HIV Clinic in Uganda and Choices made by Women.
Laker EAO, Arinaitwe A, Owarwo N, Onzia A, Nasasira B, Wailagala A, Kalule I, Anguzu G, Kiragga A, Seden K, Lwanga I, Castelnuovo B, Musomba R, Lamorde M. Laker EAO, et al. Drug Saf. 2020 Nov;43(11):1133-1140. doi: 10.1007/s40264-020-00974-9. Drug Saf. 2020. PMID: 32926356
An observational study in an urban Ugandan clinic comparing virological outcomes of patients switched from first-line antiretroviral regimens to second-line regimens containing ritonavir-boosted atazanavir or ritonavir-boosted lopinavir.
Laker EAO, Nabaggala MS, Kaimal A, Nalwanga D, Castelnuovo B, Musubire A, Kiragga A, Lamorde M, Ratanshi RP. Laker EAO, et al. BMC Infect Dis. 2019 Mar 25;19(1):280. doi: 10.1186/s12879-019-3907-5. BMC Infect Dis. 2019. PMID: 30909871 Free PMC article.